Around 15% of mUC patients harbor alterations in fibroblast growth factor receptor (FGFR), resulting in excessive stimulation of the downstream signaling cascade [59]; FGFR3 was also associated with a T-cell-depleted tumor environement and FGFR inhibition with erdafitinib was demonstrated to upregulate inflammation-related signaling. This evidence concerns the gene FGFR3 and neoplasm.